Salgado et al. [155] suggested that the primary antiviral mechanism against HIV-1 was based on inhibition of SAMHD1 phosphorylation in CD4+ T cells, which prevented ex vivo HIV-1 infection in CML patients treated with dasatinib. The gene discussed is CD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.